BioMed Alliance and 17 other civil society organisations call on policy makers to ensure that the next multiannual EU budget will be fit-for-purpose to address current and future health threats.
This is an interesting work elucidating for the first time a role for ataxin-1 (ATXN1) mutation, traditionally linked to spinocerebellar ataxia-type 1 (SCA1), in the pathogenesis of Experimental Autoimmune Encephalomyelitis (EAE), the rodent model for Multiple Sclerosis (MS)
The International Restless Legs Syndrome Study Group task force found sufficient evidence to formulate diagnostic criteria for pediatric clinical entity designated “restless sleep disorder”.
Societal Impact of Pain (SIP) is an international multi-stakeholder platform. Its long-term priorities are pain indicators, pain education, pain in employment, and pain research. This year traditional SIP Stakeholder Forum was on October 28th, 2020.
The European Brain Council (EBC) is very pleased to announce the launch of updated disease fact sheets, providing a quick overview of key facts, history, known causes, diagnosis, symptoms and treatment of brain disorders – neurological and mental alike.
The European Medicines Agency (EMA) has a Healthcare Professionals’ Working Party (HCPWP) in which EAN participates since 2013. Meetings are mostly held together with the Consumers’ and Patients’ Working Party.
This year we were especially happy to receive so many good applications and are happy to announce that we could select the below grantees for an entire support of 81 months (instead of 72 as usual).
For December 2020, we have selected the following two papers: Zhang Q et al. ''COVID-19 case fatality and Parkinson’s disease'' and Bsteh G, et al. ''Multiple sclerosis and COVID-19: how many are at risk?''